Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Retinoschisis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 9 Months to 100 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Bethesda, Maryland • Rochester, Michigan

Conditions: Retinitis Pigmentosa
Interventions: Electro-acupuncture; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 10 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
Interventions: AAV2-hRPE65v2,voretigene neparvovec-rzyl; Biological
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Miami, Florida • Iowa City, Iowa + 6 more

Conditions: Diabetic Macular Edema
Interventions: OXU-001, Semi-automated suprachoroidal illuminated microcatheter, Ozurdex® Ophthalmic Intravitreal Implant; Drug · Device
Lead sponsor: Oxular Limited; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Phoenix, Arizona • Clearwater, Florida • Oak Forest, Illinois + 5 more

Conditions: Choroideremia, X-Linked Retinitis Pigmentosa
Interventions: BIIB111, BIIB112; Genetic
Lead sponsor: NightstaRx Ltd, a Biogen Company; Other
Eligibility: 18 Years and older · Male only
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Retina Disease, Glaucoma, Normal
Interventions: P200TE, Predicate Device; Device
Lead sponsor: Optos, PLC; Industry
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Retinopathy
Interventions: Anecortave Acetate Sterile Suspension (15 mg); Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: New York, New York

Conditions: Geographic Atrophy
Interventions: Pegcetacoplan; Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 34
States / cities: Bakersfield, California • Beverly Hills, California • Fullerton, California + 28 more

Conditions: Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions: INV-102; Drug
Lead sponsor: Invirsa, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Stargardt Disease
Interventions: AAVB-039; Biological
Lead sponsor: AAVantgarde Bio Srl; Industry
Eligibility: 8 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more

Conditions: Diabetic Macular Edema
Interventions: IVT aflibercept, Sham SC, SC CLS-TA; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 29
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 25 more

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 48
States / cities: Irvine, California • Loma Linda, California • Palm Springs, California + 39 more

Conditions: Diabetic Macular Edema
Interventions: Warp 10 LED Device, Near-infrared light (NIR); Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Eye Diseases, Healthy Volunteers
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions: Arm 1; Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Westport, Connecticut • Coral Springs, Florida

Conditions: Age-Related Macular Degeneration, Macular Degeneration
Interventions: Intravitreal Aflibercept Injection; Drug
Lead sponsor: MidAtlantic Retina; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Cherry Hill, New Jersey • Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Chondrosarcoma, Osteosarcoma, Soft Tissue Sarcoma
Interventions: Abemaciclib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 4
States / cities: Jacksonville, Florida • Iowa City, Iowa • St Louis, Missouri + 1 more

Conditions: Cystoid Macular Edema, Uveitis
Interventions: Vitamin E; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Proliferative Diabetic Retinopathy (PDR)
Interventions: Aflibercept 8mg; Drug
Lead sponsor: Edward Wood, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Austin, Texas • Bellaire, Texas • San Antonio, Texas

Conditions: Proliferative Diabetic Retinopathy
Interventions: Intravitreal Aflibercept Injection (IAI); Drug
Lead sponsor: Ophthalmic Consultants of Long Island; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Lynbrook, New York

Conditions: Geographic Atrophy, Age-Related Macular Degeneration, AMD
Interventions: OT-551 antioxidant eye drop; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 60 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinopathy of Prematurity (ROP)
Interventions: Ultra-widefield Optical Coherence Tomography (UWF-OCT), Wide-field ophthalmic imaging system; Device
Lead sponsor: Duke University; Other
Eligibility: 0 Days to 9 Months
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Mild Cognitive Impairment
Interventions: Octagam 10%; Biological
Lead sponsor: Sutter Health; Other
Eligibility: 50 Years to 84 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis

Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa

A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir

P200TE Agreement and Precision Study

Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

Evaluation of Vitrectomy for Diabetic Macular Edema

Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study

Adaptive Optics Retinal Imaging

Stem Cell Ophthalmology Treatment Study II

Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Vitamin E to Treat Uveitis-Associated Macular Edema

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study

OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration

Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease